FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention is characterized by compositions containing multiple therapeutic agents, where the presence of one therapeutic agent improves properties of at least one other therapeutic agent. In one version, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR), such as a CFTR corrector or CFTR enhancer, for treating CFTR mediated diseases, such as cystic fibrosis. Methods and kits containing them are also described.
EFFECT: disclosed are pharmaceutical compositions for treating diseases mediated by a cystic fibrosis transmembrane conductance regulator.
47 cl, 15 dwg, 24 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES MEDIATED BY A TRANSMEMBRANE REGULATOR OF CYSTIC FIBROSIS (CFTR) | 2013 |
|
RU2692676C2 |
| HIGH-PERFORMANCE TEST HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD | 2015 |
|
RU2691136C2 |
| METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING CFTR MEDIATED DISEASES | 2014 |
|
RU2718044C2 |
| NEW TREATMENT | 2015 |
|
RU2688191C2 |
| SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[d][1,3]DIOXOL-5-YL)-N-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANE CARBOXAMIDE | 2011 |
|
RU2573830C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
| SOLID FORMS OF (R)-1-(2, 2-DIFLUOROBENZO[D][1, 3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | 2011 |
|
RU2711481C2 |
| SILICON-CONTAINING IVACAFTOR ANALOGUES | 2017 |
|
RU2796112C2 |
| SOLID FORMS OF N-(4-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | 2010 |
|
RU2568608C2 |
| INJECTION OF DEUTERATED CFTR AMPLIFIERS | 2016 |
|
RU2761344C2 |
